1 Min Read
June 28 (Reuters) - CELLECTIS SA:
* ANNOUNCED ON TUESDAY FIRST ADMINISTRATION IN THE PHASE I CLINICAL STUDY IN ACUTE MYELOID LEUKEMIA (AML) FOR ITS INVESTIGATIONAL PRODUCT UCART123
Source text for Eikon:
Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.